

Accepted Manuscript

Efficacy and safety of empagliflozin in Japanese patients with type 2 diabetes mellitus: A sub-analysis by body mass index and age of pooled data from three clinical trials

Teruo Shiba, So Ishii, Tomoo Okamura, Rika Mitsuyoshi, Egon Pfarr, Kazuki Koiwai

PII: S0168-8227(17)30172-9
DOI: <http://dx.doi.org/10.1016/j.diabres.2017.07.004>
Reference: DIAB 7014

To appear in: *Diabetes Research and Clinical Practice*

Received Date: 31 January 2017
Revised Date: 14 June 2017
Accepted Date: 3 July 2017

Please cite this article as: T. Shiba, S. Ishii, T. Okamura, R. Mitsuyoshi, E. Pfarr, K. Koiwai, Efficacy and safety of empagliflozin in Japanese patients with type 2 diabetes mellitus: A sub-analysis by body mass index and age of pooled data from three clinical trials, *Diabetes Research and Clinical Practice* (2017), doi: <http://dx.doi.org/10.1016/j.diabres.2017.07.004>

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.



Target journal: *Diabetes Research and Clinical Practice*

Type of manuscript: Research Article (Clinical Research)

Title:

Efficacy and safety of empagliflozin in Japanese patients with type 2 diabetes mellitus: A sub-analysis by body mass index and age of pooled data from three clinical trials

Author:

Teruo Shiba¹, So Ishii², Tomoo Okamura³, Rika Mitsuyoshi³, Egon Pfarr⁴, Kazuki Koiwai³

Institutional addresses:

1. Division of Diabetes and Metabolism, Toho University Ohashi Medical Center, 2-17-6 Ohashi, Meguro-ku, Tokyo, 153-8515, Japan.
2. Eli Lilly Japan K.K., 4-15-1, Akasaka, Minato-ku, Tokyo 107-0052 Japan
3. Nippon Boehringer Ingelheim Co.,Ltd., 2-1-1 Osaki, Shinagawa-ku, Tokyo 141-6017, Japan
4. Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim am Rhein, Germany

Email addresses:

teruo.shiba@med.toho-u.ac.jp

ishii_so@lilly.com

tomoo.okamura@boehringer-ingelheim.com

rika.mitsuyoshi@boehringer-ingelheim.com

egon.pfarr@boehringer-ingelheim.com

kazuki.koiwai@boehringer-ingelheim.com

Download English Version:

<https://daneshyari.com/en/article/5587249>

Download Persian Version:

<https://daneshyari.com/article/5587249>

[Daneshyari.com](https://daneshyari.com)